Karen Kelly Selected Research

Chemoradiotherapy

1/2021	A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811).
11/2017	A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients.
9/2017	Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.
1/2017	Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
9/2015	A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533.
1/2013	A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer.
5/2008	Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
6/2007	Current treatment paradigms for locally advanced non-small cell lung cancer.
5/2006	A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karen Kelly Research Topics

Disease

78	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 02/2002
48	Neoplasms (Cancer) 04/2024 - 02/2002
32	Lung Neoplasms (Lung Cancer) 01/2024 - 02/2002
13	Disease Progression 09/2021 - 10/2007
9	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2017 - 09/2002
7	Neutropenia 10/2018 - 08/2004
5	Exanthema (Rash) 12/2020 - 05/2005
5	Fatigue 11/2018 - 08/2004
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2024 - 01/2017
4	Carcinoma (Carcinomatosis) 01/2021 - 01/2017
4	Adenocarcinoma 01/2021 - 05/2015
3	Brain Neoplasms (Brain Tumor) 04/2024 - 08/2014
3	Diarrhea 12/2020 - 12/2015
3	Adenocarcinoma of Lung 01/2018 - 11/2015
2	Glioblastoma (Glioblastoma Multiforme) 04/2024 - 01/2023
2	Inflammation (Inflammations) 01/2024 - 01/2016
2	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 01/2019
2	Mesothelioma 01/2021 - 07/2008
2	Merkel Cell Carcinoma 01/2020 - 01/2017
2	Weight Loss (Weight Reduction) 10/2019 - 01/2015
2	Malignant Mesothelioma 10/2019 - 01/2017
2	Thrombocytopenia (Thrombopenia) 10/2018 - 01/2017
2	Mucositis 01/2017 - 06/2012
2	Breast Neoplasms (Breast Cancer) 02/2016 - 07/2009
2	Febrile Neutropenia 09/2006 - 08/2004
1	Small Cell Carcinoma 04/2024
1	Body Weight (Weight, Body) 05/2023
1	COVID-19 01/2023
1	Tyrosinemias (Tyrosinemia) 06/2022
1	Inborn Genetic Diseases (Disease, Hereditary) 06/2022

Drug/Important Bio-Agent (IBA)

19	ErbB Receptors (EGF Receptor)IBA 04/2024 - 07/2003
17	Docetaxel (Taxotere)FDA Link 01/2023 - 02/2002
17	PlatinumIBA 09/2021 - 10/2007
13	Tyrosine Kinase InhibitorsIBA 01/2022 - 07/2003
13	Cisplatin (Platino)FDA LinkGeneric 10/2019 - 02/2002
12	Biomarkers (Surrogate Marker)IBA 01/2023 - 06/2006
9	Cetuximab (Erbitux)FDA Link 01/2022 - 12/2005
9	Carboplatin (JM8)FDA LinkGeneric 01/2019 - 02/2002
9	Paclitaxel (Taxol)FDA LinkGeneric 01/2017 - 02/2002
8	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2013
8	Pemetrexed (MTA)FDA Link 10/2019 - 08/2004
7	Immune Checkpoint InhibitorsIBA 10/2023 - 12/2015
7	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2023 - 06/2012
7	avelumabIBA 04/2022 - 01/2017
5	B7-H1 AntigenIBA 01/2021 - 07/2017
5	Gefitinib (Iressa)FDA Link 05/2008 - 07/2003
4	telisotuzumab vedotinIBA 10/2023 - 11/2018
4	Immunoconjugates (Immunoconjugate)IBA 01/2023 - 11/2018
4	trametinibIBA 01/2023 - 01/2017
4	Bevacizumab (Avastin)FDA Link 01/2018 - 03/2007
4	Etoposide (VP 16)FDA LinkGeneric 09/2015 - 06/2005
4	Vinorelbine (Navelbine)FDA LinkGeneric 11/2013 - 02/2002
4	Gemcitabine FDA Link 07/2008 - 08/2004
3	NivolumabIBA 01/2024 - 01/2019
3	AfatinibIBA 01/2022 - 01/2020
3	Topotecan (Hycamtin)FDA LinkGeneric 10/2018 - 11/2006
3	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2018 - 06/2005
3	Immunoglobulin G (IgG)IBA 01/2018 - 02/2016
3	Monoclonal AntibodiesIBA 01/2017 - 07/2008
3	sulindac sulfone (exisulind)IBA 10/2007 - 02/2002
2	IpilimumabIBA 01/2024 - 09/2021
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022 - 01/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 06/2008
2	capmatinibIBA 01/2021 - 05/2017
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2021 - 09/2002
2	durvalumabIBA 01/2021 - 01/2021
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 01/2021
2	Cyclin-Dependent Kinase 4IBA 12/2019 - 10/2019
2	Angiogenesis InhibitorsIBA 10/2019 - 01/2018
2	cediranib (AZD2171)IBA 10/2019 - 01/2017
2	Anaplastic Lymphoma KinaseIBA 01/2019 - 01/2014
2	Alanine Transaminase (SGPT)IBA 11/2018 - 08/2004
2	AntibodiesIBA 01/2018 - 02/2016
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2017 - 02/2011
2	Cytostatic AgentsIBA 10/2015 - 07/2003
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2014 - 10/2003
2	Antineoplastic Agents (Antineoplastics)IBA 05/2007 - 02/2002
1	OligonucleotidesIBA 04/2024
1	Small Interfering RNA (siRNA)IBA 04/2024
1	amivantamab-vmjwIBA 04/2024
1	osimertinibIBA 04/2024
1	Eosine Yellowish-(YS) (Eosin)IBA 10/2023
1	Hematoxylin (Haematoxylon)IBA 10/2023
1	Superoxide Dismutase-1IBA 05/2023
1	atezolizumabIBA 01/2023
1	Antiviral Agents (Antivirals)IBA 01/2023
1	BESIBA 06/2022
1	RNA (Ribonucleic Acid)IBA 06/2022
1	pembrolizumabIBA 01/2022

Therapy/Procedure

34	Drug Therapy (Chemotherapy) 12/2022 - 02/2002
33	Therapeutics 04/2024 - 02/2002
11	Immunotherapy 01/2024 - 12/2015
9	Radiotherapy 01/2023 - 09/2006
9	Chemoradiotherapy 01/2021 - 05/2006
2	Adjuvant Chemotherapy 01/2022 - 07/2005
2	Duration of Therapy 11/2020 - 07/2009
2	Combined Modality Therapy 01/2019 - 12/2005
2	Induction Chemotherapy 09/2017 - 01/2017
2	Chemoprevention 05/2009 - 02/2002
1	Neoadjuvant Therapy 10/2023